EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma

P. D. Bonomi, D. Finkelstein, S. Aisner, D. Ettinger

Research output: Contribution to journalArticlepeer-review

Abstract

In 1982 there were four reports of cisplatin-induced remissions of invasive thymoma. These observations led the Eastern Cooperative Oncology Group (ECOG) to conduct a Phase II trial of cisplatin (50 mg/m2 intravenously every 3 weeks). During a 4-year period 24 patients were entered on this trial; 3 were excluded because review of histologic material failed to confirm the presence of thymoma. The characteristics of the remaining 21 patients were as follows: median age, 51; males/females, 11/10; ECOG performance status, 0-1/2-3, 16/5; previous treatment with chemotherapy, 3; previous surgery, 20; previous radiation, 15; weight loss, <5%/≥5%: 17/4. One patient was eliminated from response analysis because of failure to return for follow-up tumor measurements. The following responses were observed in the remaining 20 patients. Partial remission, 2 (10%); stable disease, 8 (40%); and progression, 10 (50%). The median survival was 76 weeks, and the 2-year survival rate was 39%. Four patients experienced severe nausea and vomiting, but life-threatening and lethal toxicities were not observed. Cisplatin given at this dose was relatively ineffective in producing tumor regression in recurrent or metastatic thymoma.

Original languageEnglish (US)
Pages (from-to)342-345
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number4
DOIs
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma'. Together they form a unique fingerprint.

Cite this